| Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. | |
| | |
MedLine Citation:
|
PMID: 20692189 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect of bisphosphonate (BP) medication. Tooth extractions are the most frequent causes for BRONJ. In some cases BRONJ is observed spontaneously, with some anatomic sites carrying a higher risk. Sunitinib, a tyrosine kinase inhibitor, is established in renal cell carcinoma and is known to lead to oral mucositis as a side effect, which in BP patients may additionally raise the risk of BRONJ. STUDY DESIGN: We present 3 patients with renal cell carcinoma under BP medication who developed BRONJ during and after sunitinib medication. RESULTS: In 2 patients, BRONJ was linked to the occurrence of mucositis after sunitinib intake. The third patient showed relapse of completely healed BRONJ lesions shortly after resumption of a sunitinib therapy. CONCLUSIONS: Oral mucositis during chemotherapy may raise the risk of BRONJ in cancer patients with BP medication. Especially in renal cell carcinoma patients under sunitinib therapy and intravenous BP medication, oral mucositis should be observed closely because it could be a risk factor for BRONJ. |
| | |
Authors:
|
Sebastian Hoefert; Harald Eufinger |
Related Documents
:
|
12931039 - Presentation and 5-year follow-up of type 2 diabetes mellitus in african-american and c... 16758649 - Venous thromboembolism in medically ill patients: identifying risk and strategies for p... 20500649 - Non-therapeutic omission of medications in acutely ill patients. 3129939 - Financial risk, hospital cost, and complications and comorbidities in medical non-compl... 16036849 - Use of treat-and-release medical directives for paramedics at a mass gathering. 20969559 - Medication dose reductions after pallidal versus subthalamic stimulation in patients wi... 10981839 - Toward understanding why fairness matters: the influence of mortality salience on react... 16585809 - Development of the purposeful action medication-taking questionnaire. 15306329 - New dinosaurs link southern landmasses in the mid-cretaceous. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2010-08-09 |
Journal Detail:
|
Title: Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics Volume: 110 ISSN: 1528-395X ISO Abbreviation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-27 Completed Date: 2011-01-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9508562 Medline TA: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Country: United States |
Other Details:
|
Languages: eng Pagination: 463-9 Citation Subset: D; IM |
Copyright Information:
|
Copyright © 2010 Mosby, Inc. All rights reserved. |
Affiliation:
|
Department of Oral and Maxillofacial Surgery, Regional Plastic Surgery, Knappschaftskrankenhaus Recklinghausen, Academic Teaching Hospital of Ruhr-University Bochum, Recklinghausen, Germany. hoefert.sebastian@kk-recklinghausen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects* Bone Density Conservation Agents / administration & dosage, adverse effects Carcinoma, Renal Cell / drug therapy* Diphosphonates / administration & dosage, adverse effects Humans Indoles / adverse effects* Injections, Intravenous Kidney Neoplasms / drug therapy* Mandibular Diseases / chemically induced*, surgery Middle Aged Mucositis / chemically induced, complications Osteonecrosis / chemically induced*, surgery Protein Kinase Inhibitors / adverse effects Protein-Tyrosine Kinases / antagonists & inhibitors Pyrroles / adverse effects* Risk Factors Stomatitis / chemically induced, complications Tooth Extraction / adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Indoles; 0/Protein Kinase Inhibitors; 0/Pyrroles; 0/sunitinib; EC 2.7.10.1/Protein-Tyrosine Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Scanning electron microscope evaluation of chlorhexidine gel and liquid associated with sodium hypoc...
Next Document: Fixation, registration, and image-guided navigation using a thermoplastic facial mask in electromagn...